

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





Figure 1.



*(R)-configuration

***(R)- or (S)-configuration

wherein

R^1 , R^2 and R^3 are each independently of the others an aliphatic hydrocarbon radical having from 7 to 21 carbon atoms,

n is 0 or 1,

As is the amidically bonded residue of a (D)- or (L)-amino acid or of a (D)- or (L)-amino acid derivative from the group consisting of Gly, Ala, Ser, Thr, Asp, Asp(R^5), Glu, Glu(R^5), Glu, Glu(R^5) and Glu(R^5)₂, and

R^4 and R^5 are each independently of the other the amidically bonded radical of an unsubstituted or carboxy-substituted α -amino-C₂-C₃alkanesulfonic acid.





Figure 2



JBT3002, $\text{C}_{55}\text{H}_{102}\text{N}_4\text{O}_{14}\text{S}_3\text{Na}_2$ (1185.6)




Figure 3





Figure 4




MLV-JT3002

(A)

- 10' 20' 30' 4h 24h


133 -
71 -
42 -
31 -



45 kD
41 kD
39 kD

kDa

β -actin



IFN γ
LPS
MLV-JT3002

+ + - + + + + +
- 15' - - - - -
- - - 5' 10' 20' 30' 120'

(B)

133 -
71 -
42 -
31 -



45 kD
41 kD
39 kD

kDa

β -actin




Figure 5







Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18






Figure 19



COPY

CONFIDENTIAL

PBS followed by CPT-11

Oral MTP-PE followed by CPT




Figure 20

O I P E
MAR 15 2004
PATENT & TRADEMARK OFFICE

COPY CONFIDENTIAL





Figure 21



ILEUM





IL-15 RT-PCR




Fig 23